vs
Side-by-side financial comparison of GRIFFON CORP (GFF) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
GRIFFON CORP is the larger business by last-quarter revenue ($649.1M vs $622.0M, roughly 1.0× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 9.9%, a 24.5% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 2.6%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -1.8%).
Griffon Corporation is a multinational conglomerate headquartered in New York City. It operates as a diversified management and holding company. The company has four subsidiaries: Ames True Temper, ClosetMaid, Clopay Building Products, and CornellCookson. Griffon has been publicly traded since 1961 and is listed on the New York Stock Exchange as a component stock of the S&P SmallCap 600, S&P Composite 1500, and Russell 2000 indices.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
GFF vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $649.1M | $622.0M |
| Net Profit | $64.4M | $214.2M |
| Gross Margin | 41.1% | — |
| Operating Margin | 17.5% | 62.4% |
| Net Margin | 9.9% | 34.4% |
| Revenue YoY | 2.6% | 4.8% |
| Net Profit YoY | -9.1% | 2.9% |
| EPS (diluted) | $1.41 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $649.1M | $622.0M | ||
| Q3 25 | $662.2M | $609.3M | ||
| Q2 25 | $613.6M | $578.7M | ||
| Q1 25 | $611.7M | $568.2M | ||
| Q4 24 | $632.4M | $593.6M | ||
| Q3 24 | $659.7M | $564.7M | ||
| Q2 24 | $647.8M | $537.3M | ||
| Q1 24 | $672.9M | $568.0M |
| Q4 25 | $64.4M | $214.2M | ||
| Q3 25 | $43.6M | $288.2M | ||
| Q2 25 | $-120.1M | $30.2M | ||
| Q1 25 | $56.8M | $238.3M | ||
| Q4 24 | $70.9M | $208.2M | ||
| Q3 24 | $62.5M | $544.0M | ||
| Q2 24 | $41.1M | $102.0M | ||
| Q1 24 | $64.1M | $4.8M |
| Q4 25 | 41.1% | — | ||
| Q3 25 | 41.7% | — | ||
| Q2 25 | 43.2% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 41.8% | — | ||
| Q3 24 | 39.9% | — | ||
| Q2 24 | 38.5% | — | ||
| Q1 24 | 40.2% | — |
| Q4 25 | 17.5% | 62.4% | ||
| Q3 25 | 18.0% | 70.1% | ||
| Q2 25 | -20.5% | 36.3% | ||
| Q1 25 | 16.5% | 94.0% | ||
| Q4 24 | 17.7% | 60.9% | ||
| Q3 24 | 16.9% | — | ||
| Q2 24 | 13.8% | 50.2% | ||
| Q1 24 | 16.9% | -13.0% |
| Q4 25 | 9.9% | 34.4% | ||
| Q3 25 | 6.6% | 47.3% | ||
| Q2 25 | -19.6% | 5.2% | ||
| Q1 25 | 9.3% | 41.9% | ||
| Q4 24 | 11.2% | 35.1% | ||
| Q3 24 | 9.5% | 96.3% | ||
| Q2 24 | 6.3% | 19.0% | ||
| Q1 24 | 9.5% | 0.8% |
| Q4 25 | $1.41 | $0.49 | ||
| Q3 25 | $1.04 | $0.67 | ||
| Q2 25 | $-2.65 | $0.07 | ||
| Q1 25 | $1.21 | $0.55 | ||
| Q4 24 | $1.49 | $0.46 | ||
| Q3 24 | $1.29 | $1.21 | ||
| Q2 24 | $0.84 | $0.23 | ||
| Q1 24 | $1.28 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $95.3M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $108.9M | $9.7B |
| Total Assets | $2.1B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $618.7M | ||
| Q3 25 | $99.0M | $938.9M | ||
| Q2 25 | $107.3M | $631.9M | ||
| Q1 25 | $127.8M | $1.1B | ||
| Q4 24 | $152.0M | $929.0M | ||
| Q3 24 | $114.4M | $950.1M | ||
| Q2 24 | $133.5M | $1.8B | ||
| Q1 24 | $123.0M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | $1.5B | $8.0B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.5B | $7.6B | ||
| Q3 24 | $1.5B | $7.6B | ||
| Q2 24 | $1.5B | $7.6B | ||
| Q1 24 | $1.6B | $6.1B |
| Q4 25 | $108.9M | $9.7B | ||
| Q3 25 | $74.0M | $9.6B | ||
| Q2 25 | $63.9M | $9.5B | ||
| Q1 25 | $214.7M | $9.8B | ||
| Q4 24 | $227.8M | $10.3B | ||
| Q3 24 | $224.9M | $10.3B | ||
| Q2 24 | $223.5M | $9.8B | ||
| Q1 24 | $202.2M | $9.9B |
| Q4 25 | $2.1B | $19.6B | ||
| Q3 25 | $2.1B | $19.3B | ||
| Q2 25 | $2.1B | $18.3B | ||
| Q1 25 | $2.3B | $17.6B | ||
| Q4 24 | $2.3B | $18.2B | ||
| Q3 24 | $2.4B | $18.0B | ||
| Q2 24 | $2.4B | $17.7B | ||
| Q1 24 | $2.4B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | 22.71× | 0.84× | ||
| Q1 25 | 7.16× | 0.78× | ||
| Q4 24 | 6.48× | 0.74× | ||
| Q3 24 | 6.78× | 0.74× | ||
| Q2 24 | 6.74× | 0.78× | ||
| Q1 24 | 7.84× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $107.0M | $827.1M |
| Free Cash FlowOCF − Capex | $99.3M | — |
| FCF MarginFCF / Revenue | 15.3% | — |
| Capex IntensityCapex / Revenue | 1.2% | — |
| Cash ConversionOCF / Net Profit | 1.66× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $278.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $107.0M | $827.1M | ||
| Q3 25 | $75.0M | $702.6M | ||
| Q2 25 | $123.1M | $364.0M | ||
| Q1 25 | $16.5M | $596.1M | ||
| Q4 24 | $142.9M | $742.5M | ||
| Q3 24 | $72.1M | $703.6M | ||
| Q2 24 | $122.1M | $658.2M | ||
| Q1 24 | $39.8M | $664.6M |
| Q4 25 | $99.3M | — | ||
| Q3 25 | $62.4M | — | ||
| Q2 25 | $114.4M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | $125.5M | — | ||
| Q3 24 | $51.6M | — | ||
| Q2 24 | $107.5M | — | ||
| Q1 24 | $20.8M | — |
| Q4 25 | 15.3% | — | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 18.6% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 16.6% | — | ||
| Q1 24 | 3.1% | — |
| Q4 25 | 1.2% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.8% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 2.8% | — |
| Q4 25 | 1.66× | 3.86× | ||
| Q3 25 | 1.72× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 0.29× | 2.50× | ||
| Q4 24 | 2.02× | 3.57× | ||
| Q3 24 | 1.15× | 1.29× | ||
| Q2 24 | 2.97× | 6.45× | ||
| Q1 24 | 0.62× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GFF
| Consumer And Professional Products | $241.1M | 37% |
| Residential Repairand Remodel | $202.1M | 31% |
| International Excluding North America | $97.8M | 15% |
| Retail | $47.3M | 7% |
| Residential New Construction | $32.5M | 5% |
| Other | $14.2M | 2% |
| Industrial | $14.1M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
